Title : Carmofur (ASAH1 inhibitor) is more potent than TMZ in killing glioblastoma cells?
link : Carmofur (ASAH1 inhibitor) is more potent than TMZ in killing glioblastoma cells?
Carmofur (ASAH1 inhibitor) is more potent than TMZ in killing glioblastoma cells?
I found an interesting study published in November 2017:
https://www.ncbi.nlm.nih.gov/pubmed/29348854
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=22637&path[]=71521
"The standard glioblastoma chemotherapy agent, temozolomide, had minimal GSC-targeted effects at comparable or even higher concentrations (IC50 > 750 μM against GSCs). ASAH1 is identified as a de novo glioblastoma drug target, and ASAH1 inhibitors, such as carmofur, are shown to be highly effective and to specifically target glioblastoma GSCs. Carmofur is an ASAH1 inhibitor that crosses the blood-brain barrier, a major bottleneck in glioblastoma treatment. It has been approved in Japan since 1981 for colorectal cancer therapy. Therefore, it is poised for repurposing and translation to glioblastoma clinical trials."
"ASAH1 inhibitors are highly more potent than temozolomide in killing GSCs and U87MG cells. Due to its high level of expression in GSCs, ASAH1 inhibition is proposed as a new anti-glioblastoma therapy that specifically targets GSCs."
2017 https://www.ncbi.nlm.nih.gov/pubmed/28765947
"inhibition of ASAH1 and Sph-1P, either with humanized monoclonal antibodies, small molecule drugs (i.e. carmofur), or a combination of both, led to suppression of GBM cell growth. These results suggest that ASAH1 and Sph-1P may be excellent targets for the treatment of new GBMs and recurrent GBMs, especially since the latter overexpresses ASAH1."
https://www.drugs.com/international/carmofur.html
Unfortunately, I did not find any trials with carmofur (or mifurol) at http://ift.tt/1pydFNc
https://en.wikipedia.org/wiki/Carmofur
"Carmofur has also been used as adjuvant chemotherapy for curatively resected colorectal cancer patients in China, Japan, and Finland for many years. Trials and meta-analyses have confirmed that the drug is effective on patients with this cancer type, extending their survival.
A clinical trial for small hepatocellular carcinoma was stopped prematurely because 56% of the treated patients had unacceptable side effects. Moreover, the treatment had no survival advantage for stage 1 and 2 cancer patients. This may be a reason why carmofur was never pursued for FDA-approval in the US."
Maybe there are more modern and safe ASAH1 inhibitors crossing the blood-brain barrier?
https://www.ncbi.nlm.nih.gov/pubmed/29348854
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=22637&path[]=71521
"The standard glioblastoma chemotherapy agent, temozolomide, had minimal GSC-targeted effects at comparable or even higher concentrations (IC50 > 750 μM against GSCs). ASAH1 is identified as a de novo glioblastoma drug target, and ASAH1 inhibitors, such as carmofur, are shown to be highly effective and to specifically target glioblastoma GSCs. Carmofur is an ASAH1 inhibitor that crosses the blood-brain barrier, a major bottleneck in glioblastoma treatment. It has been approved in Japan since 1981 for colorectal cancer therapy. Therefore, it is poised for repurposing and translation to glioblastoma clinical trials."
"ASAH1 inhibitors are highly more potent than temozolomide in killing GSCs and U87MG cells. Due to its high level of expression in GSCs, ASAH1 inhibition is proposed as a new anti-glioblastoma therapy that specifically targets GSCs."
2017 https://www.ncbi.nlm.nih.gov/pubmed/28765947
"inhibition of ASAH1 and Sph-1P, either with humanized monoclonal antibodies, small molecule drugs (i.e. carmofur), or a combination of both, led to suppression of GBM cell growth. These results suggest that ASAH1 and Sph-1P may be excellent targets for the treatment of new GBMs and recurrent GBMs, especially since the latter overexpresses ASAH1."
https://www.drugs.com/international/carmofur.html
Unfortunately, I did not find any trials with carmofur (or mifurol) at http://ift.tt/1pydFNc
https://en.wikipedia.org/wiki/Carmofur
"Carmofur has also been used as adjuvant chemotherapy for curatively resected colorectal cancer patients in China, Japan, and Finland for many years. Trials and meta-analyses have confirmed that the drug is effective on patients with this cancer type, extending their survival.
A clinical trial for small hepatocellular carcinoma was stopped prematurely because 56% of the treated patients had unacceptable side effects. Moreover, the treatment had no survival advantage for stage 1 and 2 cancer patients. This may be a reason why carmofur was never pursued for FDA-approval in the US."
Maybe there are more modern and safe ASAH1 inhibitors crossing the blood-brain barrier?
Thus Article Carmofur (ASAH1 inhibitor) is more potent than TMZ in killing glioblastoma cells?
That's an article Carmofur (ASAH1 inhibitor) is more potent than TMZ in killing glioblastoma cells? This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Carmofur (ASAH1 inhibitor) is more potent than TMZ in killing glioblastoma cells? with the link address https://polennews.blogspot.com/2018/01/carmofur-asah1-inhibitor-is-more-potent.html
0 Response to "Carmofur (ASAH1 inhibitor) is more potent than TMZ in killing glioblastoma cells?"
Post a Comment